Abstract
Unani system of Medicine is documented with several forms of hepatitis along with their treatment through traditional drugs. The purpose of our study was to assess the effect of a formulation of Unani Medicine in the treatment of chronic Hepatitis B (CHB) cases and to collect data to warrant further clinical trials. We conducted a case series with five patient of CHB, subsequently treated with a Unani formulation as the main medicine. Cases were confirmed with standard hepatitis antigen and viral measurements. Patient were treated for 6 months with measurement of HBV DNA quantitative value. CVR (complete virological response) was observed within an average 14 weeks of treatment marked by undetectable HBV DNA in the blood. We reviewed the literature related to the Unani formalation used for the treatment in this cases. Its constituents have exhibited antiviral, anti-inflammatory, immunomodulatory, antioxidant and hepatoprotective activities, could be the possible mechanisms of action in this cases. The preliminary findings indicate the potential therapeutic role of this Unani formulation. Further studies should be conducted to explore the mechanism and action of this Unani formulation.
